Rakhi talks to Antonio about newer therapies for lipid management, incliseran and bemepdoic acid. They discuss their place in therapy and how they may be initiated in primary care.

This is the final part of our three-part series.

Antonio Ochoa-Ferraro: Consultant Pharmacist, Inherited Metabolic Disorders; University Hospitals of Birmingham

Rakhi Aggarwal: Primary Care Lead, Medicines Use and Safety; NHS SPS

Useful links

Cholesterol and Cholesterol levels

https://www.heartuk.org.uk/cholesterol/overview

NICE guidance

Inclisiran: https://www.nice.org.uk/guidance/TA733

Bempedopic acid with ezetimibe: https://www.nice.org.uk/guidance/ta694

NHS England summary of national guidance for lipid management

https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/

NHS Birmingham and Solihull ICB procurement & prescribing of inclisiran

https://www.birminghamandsurroundsformulary.nhs.uk/docs/files/Procurement%20and%20Prescribing%20of%20Inclisiran.pdf?UNLID=93161104220252141045

Novartis inclisiran resources

https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/leqvio/resources

Open Access Articles

Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran

https://pubmed.ncbi.nlm.nih.gov/38456415/

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

https://pubmed.ncbi.nlm.nih.gov/38753448/

Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis

https://pubmed.ncbi.nlm.nih.gov/39921511/

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

https://pubmed.ncbi.nlm.nih.gov/23956253/